Selected data models

You must log in to select data models for download or further analysis.

4 Search results.
Relevance Rating New first Old first

Baseline study (T0) – Risk Factors / Sonography in angiology / Randomization VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Baseline study (T0) – Risk Factors / Sonography in angiology / Randomization

- 9/13/16 - 1 form, 4 itemgroups, 51 items, 1 language
Itemgroups: Comorbidity, risk factor Thrombosis, Ultrasonography, registration; Randomization
Study documentation part: Baseline study (T0) – Risk Factors / Sonography in angiology / Randomization, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

dbGaP phs000974 NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study - Eligibility

- 12/1/23 - 4 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Vasan Ramachandran, Department of Medicine, Boston University School of Medicine, Boston, MA, USA MeSH: Cardiovascular Diseases,Atherosclerosis,Atrial Fibrillation,Death, Sudden, Cardiac,Diabetes Mellitus, Type 2,Heart Failure,Blood Pressure,Hypertension,Body Mass Index,Adiposity,Lipids,Pulmonary Disease, Chronic Obstructive,Renal Insufficiency, Chronic,Stroke,Osteoporosis,Risk Factors,Biological Markers,Biomarkers, Pharmacological https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000974 The Framingham Heart Study (FHS) is a prospective cohort study of 3 generations of subjects who have been followed up to 65 years to evaluate risk factors for cardiovascular disease. Its large sample of ~15,000 men and women who have been extensively phenotyped with repeated examinations make it ideal for the study of genetic associations with cardiovascular disease risk factors and outcomes. DNA samples have been collected and immortalized since the mid-1990s and are available on ~8000 study participants in 1037 families. These samples have been used for collection of GWAS array data and exome chip data in nearly all with DNA samples, and for targeted sequencing, deep exome sequencing and light coverage whole genome sequencing in limited numbers. Additionally, mRNA and miRNA expression data, DNA methylation data, metabolomics and other 'omics data are available on a sizable portion of study participants. This project will focus on deep whole genome sequencing (mean 30X coverage) in ~4100 subjects and imputed to all with GWAS array data to more fully understand the genetic contributions to cardiovascular, lung, blood and sleep disorders. Comprehensive phenotypic and pedigree data for study participants are available through dbGaP phs000007.

pht004909.v3.p3

1 itemgroup 2 items

pht004910.v4.p3

1 itemgroup 2 items

pht004911.v3.p3

1 itemgroup 9 items

GSK Eltrombopag Thrombocytopenia, Clinical Study ID: 105122 - Ocular History and Risk Factors

- 12/12/20 - 1 form, 3 itemgroups, 17 items, 1 language
Itemgroups: Administrative Data, ocular history and risk factors, cataract risk factors
The primary objective of this study was to demonstrate bioequivalence between eltrombopag oral film-coated tablets manufactured at Research and Development (R&D) and Commercial sites. The subject participants each went through two dosing periods (Period 1 and Period 2), during each of which they received a single dose of eltrombopag. The dosing periods were separated by a washout of at least 10 days. For each period, subjects had to perform a visit on the day before and one on the day of the administration of the drug. Furthermore, the protocol-defined visits included a screening visit, a follow-up visit, a logs and repeats visit, a PGx visit and a visit for the common CRF. Study ID: 105122 Clinical Study ID: 105122 Study Title: Phase I Bioequivalence Study for SB 497115 GR Phase II and Phase III Tablets Sponsor: GlaxoSmithKline Phase: phase 1 Study Recruitment Status: Completed Generic Name: Eltrombopag Study Indication: Thrombocytopenia This form has to be filled out at the Screening Visit.

DZHK Data Catalogue - Anamnesis and Clinical Diagnoses (incl. Basic Data Set)

- 10/17/19 - 1 form, 11 itemgroups, 91 items, 2 languages
Itemgroups: General anamnesis information, Physical Examination and Sociodemographic Data, Cardiovascular risk factors, Cardiac Diagnoses (Anamnesis and Previous Findings), Previous cardiovascular interventions, Current secondary diagnoses, Anamnesis women, Resting blood pressure, Resting heart rate, Further diagnoses, Laboratory diagnostics (blood)
With permission from the DZHK administrative office. http://dzhk.de The DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.; German Center for Cardiovascular Research) is a joint cooperation of twenty-eight institutions in seven locations throughout Germany to develop a common research strategy. They developed a data catalogue with metadata and data as well as information about available biological materials from all their studies. For more information on the data catalogue and access to actual data and biosamples please visit https://dzhk.de/en/resources/data-manual/ . This version contains the metadata part only. This form contains the mandatory basic data set with 42 items, which are recorded in all of the DZHK's studies, as well as other items related to Anamnesis and Clinical Diagnosis. This form is used to accurately record known cardiovascular risk factors, previous diagnoses and interventions, enabling a detailed assessment of a patient’s cardiovascular risk. The 42 basic items are marked as mandatory. The examination is to be performed according to the DZHK's SOPs, which can be accessed at https://dzhk.de/en/resources/sops/ (or https://dzhk.de/ressourcen/sops/ for the German language versions). The SOPs for this form are "Basic data - Anamnesis/Clinical Diagnoses/physical examination" (version 1.0, valid as of 01/09/2014) and "Anamnesis/Clinical Diagnoses" (version 1.0, valid as of 01/09/2014) for the English language version, and "Basisdatensatz – Anamnese/Klinische Diagnosen/Körperliche Untersuchung" (version 1.1, valid as of June 2019) and "Anamnese/Klinische Diagnosen" (version 1.0, valid as of 01/09/2014) for the German language version.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial